» Articles » PMID: 38491427

Using Team-based Precision Medicine to Advance Understanding of Rare Genetic Brain Disorders

Overview
Publisher Biomed Central
Specialties Neurology
Psychiatry
Date 2024 Mar 16
PMID 38491427
Authors
Affiliations
Soon will be listed here.
Abstract

We describe a multidisciplinary teamwork approach known as "Operation IDD Gene Team" developed by the Rose F. Kennedy Intellectual and Developmental Disabilities Research Center (RFK IDDRC) at the Albert Einstein College of Medicine. This initiative brings families affected by rare genetic diseases that cause intellectual and developmental disability together with physicians, basic scientists, and their trainees. At team meetings, family members share their child's medical and personal history, physicians describe the broader clinical consequences of the condition, and scientists provide accessible tutorials focused on the fundamental biology of relevant genes. When appropriate, possible treatment approaches are also discussed. The outcomes of team meetings have been overwhelmingly positive, with families not only expressing deep gratitude, but also becoming empowered to establish foundations dedicated to their child's specific condition. Physicians, and in particular the scientists and their trainees, have gained a deeper understanding of challenges faced by affected families, broadening their perspective on how their research can extend beyond the laboratory. Remarkably, research by the scientists following the Gene Team meetings have often included focus on the actual gene variants exhibited by the participating children. As these investigations progress and newly created foundations expand their efforts, national as well as international collaborations are forged. These developments emphasize the importance of rare diseases as windows into previously unexplored molecular and cellular processes, which can offer fresh insights into both normal function as well as more common diseases. Elucidating the mechanisms of and treatments for rare and ultra-rare diseases thus has benefits for all involved-families, physicians, and scientists and their trainees, as well as the broader medical community. While the RFK IDDRC's Operation IDD Gene Team program has focused on intellectual disabilities affecting children, we believe it has the potential to be applied to rare genetic diseases impacting individuals of any age and encompassing a wide variety of developmental disorders affecting multiple organ systems.

References
1.
Poirier K, Lebrun N, Broix L, Tian G, Saillour Y, Boscheron C . Mutations in TUBG1, DYNC1H1, KIF5C and KIF2A cause malformations of cortical development and microcephaly. Nat Genet. 2013; 45(6):639-47. PMC: 3826256. DOI: 10.1038/ng.2613. View

2.
Vissers L, de Ligt J, Gilissen C, Janssen I, Steehouwer M, De Vries P . A de novo paradigm for mental retardation. Nat Genet. 2010; 42(12):1109-12. DOI: 10.1038/ng.712. View

3.
Mao M, Alavi M, Labelle-Dumais C, Gould D . Type IV Collagens and Basement Membrane Diseases: Cell Biology and Pathogenic Mechanisms. Curr Top Membr. 2015; 76:61-116. DOI: 10.1016/bs.ctm.2015.09.002. View

4.
Auvin S, Holder-Espinasse M, Lamblin M, Andrieux J . Array-CGH detection of a de novo 0.7-Mb deletion in 19p13.13 including CACNA1A associated with mental retardation and epilepsy with infantile spasms. Epilepsia. 2009; 50(11):2501-3. DOI: 10.1111/j.1528-1167.2009.02189.x. View

5.
Hafezparast M, Klocke R, Ruhrberg C, Marquardt A, Ahmad-Annuar A, Bowen S . Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science. 2003; 300(5620):808-12. DOI: 10.1126/science.1083129. View